| HOME >> BIOLOGY >> TECHNOLOGY |
FIRAZYR - HAE
During the second half of 2008 FIRAZYR was launched in some countries in Europe, and sales of $0.5 million were recognized (2007: $nil). Launches will continue across Europe through 2009 as reimbursement negotiations successfully conclude. FIRAZYR has orphan exclusivity in the EU until 2018.
3. Royalties
Royalty revenue decreased by 1% to $245.5 million for the year ended December 31, 2008 (2007: $247.2 million). The following table provides an analysis of Shire's royalty income:
Royalties
to Shire
Royalty (1)
Product $M Growth
3TC 140.2 -4%
ZEFFIX 40.3 -2%
Other 65.0 +7%
Total 245.5 -1%
(1) Compared with 2007
3TC - HIV infection and AIDS
Royalties from sales of 3TC for the year to December 31, 2008 were $140.2 million, a decrease of 4% compared to the same period in 2007 (2007: $145.3 million). Excluding favorable foreign exchange movements of 2%, there has been a decline of 6% compared to the same period in 2007.
Shire receives royalties from GSK on worldwide 3TC sales. GSK's worldwide sales of 3TC for the year to December 31, 2008 were $1,060 million, a decrease of 5% compared to the same period in 2007 (2007: $1,110 million), but a decrease of approximately 7% on a constant exchange rate basis. While the nucleoside analogue market for HIV has continued to grow, competitive pressures within the market have increased, leading to a decline in 3TC sales.
'/>"/>| SOURCE Shire Plc Copyright©2009 PR Newswire. All rights reserved |